Pre-exposure prophylaxis (PrEP) is an experimental HIV-prevention strategy using
antiretroviral (ARV) agents to protect HIV negative individuals from HIV infection.TMC278 is
a new drug being developed for this type of HIV treatment. It is hoped that this drug may be
used to help prevent HIV transmission in future. A 'long acting' formulation of TMC278 has
been developed. Long acting means that the drug will be present in the blood for longer. It
is this formulation of the drug that will be investigated in this study. Subjects will
receive the drug by injection.
The purpose of this study is to investigate the safety of the drug and how well it is
tolerated by the body. The study will look at the levels of the study drug in the subjects
blood over the duration of the study.